CAR-T Warning Refinements Coming Soon From US FDA

 
• By Michael McCaughan

The US FDA is expected to refine warnings recently added to CAR-T cell therapies about the risk of secondary malignancies after reassuring new data, which is a positive sign for the future of the therapies in autoimmune disorders.

Peter Marks said the warning about secondary malignancy in CAR-T therapies soon will be revised. (Shutterstock)

More from Cell & Gene Therapies

More from Drug Safety